Evidence map›Paper›PMID 25087996›Full record

ArticleActa pharmacologica Sinica2014

Ezetimibe suppresses cholesterol accumulation in lipid-loaded vascular smooth muscle cells in vitro via MAPK signaling.

Li Qin, Yun-bo Yang, Yi-xin Yang, Neng Zhu, Yong-zhen Gong, Cai-ping Zhang, Shun-xiang Li, Duan-fang Liao

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmacologica Sinica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. SREBP1 regulatesMolecular therapy. Nucleic acids · 2022
    Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Li Qin1] Division of Stem Cell Regulation and Application, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China [2] Institute of Pharmacy and Pharmacology, South China University, Hengyang 421001, China.
Yun-bo Yang1] Division of Stem Cell Regulation and Application, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China [2] Matthew Mailing Centre for Translational Transplantation Studies, London Health Sciences Centre, Western University, London N6A5A5, Canada [3] The Second Xiang-Ya Hospital, Central South University, Changsha 410011, China.
Yi-xin YangMatthew Mailing Centre for Translational Transplantation Studies, London Health Sciences Centre, Western University, London N6A5A5, Canada.
Neng Zhu1] The Second Xiang-Ya Hospital, Central South University, Changsha 410011, China [2] The Second Affiliated Hospital, South China University, Hengyang 421001, China.
Yong-zhen Gong1] Division of Stem Cell Regulation and Application, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China [2] Department of Pharmacology, Central South University, Changsha 410011, China.
Cai-ping ZhangInstitute of Pharmacy and Pharmacology, South China University, Hengyang 421001, China.
Shun-xiang LiDivision of Stem Cell Regulation and Application, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Duan-fang LiaoDivision of Stem Cell Regulation and Application, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Hunan University · CNWestern University · CACentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the mechanisms of anti-atherosclerotic action of ezetimibe in rat vascular smooth muscle cells (VSMCs) in vitro.

methodsVSMCs of SD rats were cultured in the presence of Chol:MβCD (10 μg/mL) for 72 h, and intracellular lipid droplets and cholesterol levels were evaluated using Oil Red O staining, HPLC and Enzymatic Fluorescence Assay, respectively. The expression of caveolin-1, sterol response element-binding protein-1 (SREBP-1) and ERK1/2 were analyzed using Western blot assays. Translocation of SREBP-1 and ERK1/2 was detected with immunofluorescence.

resultsTreatment with Chol:MβCD dramatically increased the cellular levels of total cholesterol (TC), cholesterol ester (CE) and free cholesterol (FC) in VSMCs, which led to the formation of foam cells. Furthermore, Chol:MβCD treatment significantly decreased the expression of caveolin-1, and stimulated the expression and nuclear translocation of SREBP-1 in VSMCs. Co-treatment with ezetimibe (3 μmol/L) significantly decreased the cellular levels of TC, CE and FC, which was accompanied by elevation of caveolin-1 expression, and by a reduction of SREBP-1 expression and nuclear translocation. Co-treatment with ezetimibe dose-dependently decreased the expression of phosphor-ERK1/2 (p-ERK1/2) in VSMCs. The ERK1/2 inhibitor PD98059 (50 μmol/L) altered the cholesterol level and the expression of p-ERK1/2, SREBP-1 and caveolin-1 in the same manner as ezetimibe did.

conclusionEzetimibe suppresses cholesterol accumulation in rat VSMCs in vitro by regulating SREBP-1 and caveolin-1 expression, possibly via the MAPK signaling pathway.

Indexed as

AnimalsAzetidinesCholesterolEzetimibeLipidsMaleMitogen-Activated Protein KinasesMuscle, Smooth, VascularMyocytes, Smooth MuscleRatsRats, Sprague-DawleySignal TransductionAzetidinesCholesterolEzetimibeLipidsMitogen-Activated Protein Kinases

Identifiers

PMID25087996
PMCPMC4155523
OpenAlexW1997227981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.